Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics (vol 15, pg 1947, 2014)

被引：0
|
作者：
Tay-Sontheimer, J.
Shireman, L. M.
Beyer, R. P.
机构：
来源：
PHARMACOGENOMICS | 2015年 / 16卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：913 / 913
页数：1
相关论文
共 50 条
  • [21] The CYP2D6 humanized mouse:: effect of the human CYP2D6 transgene and HNF4α on the disposition of debrisoquine in the mouse (vol 60, pg 1260, 2001)
    Corchero, J
    Granvil, CP
    Akiyama, TE
    Hayhurst, GP
    Pimprale, S
    Feigenbaum, L
    Idle, JR
    Gonzalez, FJ
    MOLECULAR PHARMACOLOGY, 2002, 61 (01) : 248 - 248
  • [22] Rapid detection of the ultraextensive metabolizer associated CYP2D6*35 polymorphism.
    Steimer, W
    Bachofer, J
    Leucht, S
    Müller, B
    CLINICAL CHEMISTRY, 2002, 48 (06) : A45 - A45
  • [23] Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity
    Marchioni, E
    Perucca, E
    Soragna, D
    Bo, P
    Malaspina, A
    Ferrandi, D
    Albergati, A
    Savoldi, F
    NEUROLOGY, 1996, 46 (03) : 853 - 853
  • [24] DETERMINATION OF CYP2D6 PHENOTYPING FOR METOPROLOL USING THE CYP2D6 GENOTYPE-DERIVED ACTIVITY SCORE: RESULTS FROM A PROSPECTIVE, CLINICAL TRIAL.
    Thomas, C. D.
    Mosley, S. A.
    El Rouby, N.
    Kim, S.
    Lingineni, K.
    Langaee, T.
    Gong, Y.
    Johnson, J. A.
    Schmidt, S. O.
    Schmidt, S.
    Frye, R. F.
    Cavallari, L. H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S40 - S40
  • [25] Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity
    Magliocco, Gaelle
    Desmeules, Jules
    Matthey, Alain
    Quiros-Guerrero, Luis M.
    Bararpour, Nasim
    Joye, Timothee
    Marcourt, Laurence
    Queiroz, Emerson F.
    Wolfender, Jean-Luc
    Gloor, Yvonne
    Thomas, Aurelien
    Daali, Youssef
    BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (23) : 4708 - 4725
  • [26] Simple and Robust Detection of CYP2D6 Gene Deletions and Duplications Using CYP2D8P as Reference
    Larsen, Jens Borggaard
    Jorgensen, Steffen
    PHARMACEUTICALS, 2022, 15 (02)
  • [27] RETRACTED: CYP2D6 Is Inducible by Endogenous and Exogenous Corticosteroids (Retracted article. See vol. 46, pg. 1360, 2018)
    Farooq, Muhammad
    Kelly, Edward J.
    Unadkat, Jashvant D.
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (05) : 750 - 757
  • [28] Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data (vol 21, pg 251, 2021)
    Chen, Xiao
    Shen, Fei
    Gonzaludo, Nina
    Malhotra, Alka
    Rogert, Cande
    Taft, Ryan J.
    Bentley, David R.
    Eberle, Michael A.
    PHARMACOGENOMICS JOURNAL, 2022, 22 (5-6): : 308 - 308
  • [29] In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation (vol 123, pg 85, 2017)
    Sager, Jennifer E.
    Tripathy, Sasmita
    Price, Lauren S. L.
    Nath, Abhinav
    Chang, Justine
    Stephenson-Famy, Alyssa
    Isoherranen, Nina
    BIOCHEMICAL PHARMACOLOGY, 2021, 183
  • [30] Polymorphisms of the GSTM1 and CYP2D6 genes associated with susceptibility to lung cancer in Chinese (vol 444, pg 441, 1999)
    Gao, Y
    Zhang, Q
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2000, 464 (02) : 311 - 311
12345